ResearchMoz

Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019

GlobalData
Published Date » 2012-06-18
No. Of Pages » 65
   
 GlobalData, the industry analysis specialist, has released its new report, Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases,...
Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Hepatitis A Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.2.1 Historical Vaccination Coverage (2006-2011) 9
2.2.2 Forecast Vaccination Coverage (2011-2019) 9
2.3 Prognosis 10
2.4 Etiology 10
2.5 Pathophysiology 12
2.6 Signs and Symptoms 13
2.7 Diagnosis 14
2.8 Treatment and Management Options 16
2.9 Referral Pathway 18
2.10 GlobalData Pipeline Report Guidance 20

3 Hepatitis A Preventive Vaccines - Market Characterization 21
3.1 Global Hepatitis A Preventive Vaccines Market Size (2006-2011) 21
3.2 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Global 22
3.3 Hepatitis A Preventive Vaccines Market Size (2006-2011) - The US 23
3.4 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - The US 24
3.5 Hepatitis A Preventive Vaccines Market Size (2006-2011) - France 25
3.6 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - France 26
3.7 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Germany 27
3.8 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Germany 28
3.9 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Italy 29
3.10 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Italy 30
3.11 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Spain 31
3.12 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Spain 32
3.13 Hepatitis A Preventive Vaccines Market Size (2006-2011) - The UK 33
3.14 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - The UK 34
3.15 Hepatitis A Preventive Vaccines Market Size (2006-2011) - Japan 35
3.16 Hepatitis A Preventive Vaccines Market Forecast (2011-2019) - Japan 36
3.17 Drivers and Barriers for the Hepatitis A Preventive Vaccines Market 37
3.17.1 Drivers for the Hepatitis A Preventive Vaccines Market 37
3.17.2 Barriers for the Hepatitis A Preventive Vaccines Market 37
3.18 Opportunity and Unmet Need Analysis 38
3.19 Key Takeaway 39

4 Hepatitis A Preventive Vaccines - Competitive Assessment 40
4.1 Overview 40
4.2 Strategic Competitor Assessment 40
4.3 Product Profiles for the Major Marketed class of Products in the Hepatitis A Market 41
4.3.1 Havrix 41
4.3.2 Vaqta 42
4.3.3 Twinrix 44
4.3.4 Ambirix 45
4.3.5 Avaxim 46
4.3.6 Epaxal 46
4.4 Key Takeaway 47

5 Hepatitis A Preventive Vaccines - Clinical Trials Mapping 48
5.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 48
5.2 Clinical Trials by Phase 49
5.3 Clinical Trials by Trial Status 50
5.4 Prominent Sponsors 51
5.5 Clinical Trials by Overall Sponsors 52
5.6 Top Companies Participating in Hepatitis A Preventive Vaccines Clinical Trials 53

6 Hepatitis A Preventive Vaccines - Strategic Assessment 54
6.1 Key Events Impacting the Future Market 54
6.2 Hepatitis A Preventive Vaccines: Implications for Future Market Competition 55

7 Hepatitis A Preventive Vaccines - Future Players 56
7.1 Introduction 56
7.2 Company Profiles 56
7.2.1 GlaxoSmithKline 56
7.2.2 Merck & Co 56
7.2.3 Crucell 57

8 KOL Insights 58

9 Hepatitis A Preventive Vaccines - Appendix 59

9.1 Market Definitions 59
9.2 Abbreviations 59
9.3 Bibliography 60
9.4 Methodology 61
9.4.1 Coverage 61
9.4.2 Secondary Research 61
9.4.3 Forecasting 62
9.4.4 Primary Research 64
9.4.5 Expert Panel Validation 65
9.5 Contact Us 65
9.6 Disclaimer 65

List of Tables


Table 1: Comparison between Hepatitis A, B and C 7
Table 2: HAV Endemicity by Region 8
Table 3: Vaccination Coverage (In Percentage) 9
Table 4: Vaccination Coverage (In Percentage) 9
Table 5: History and Physical Examination 14
Table 6: Laboratory and Other Studies for Hepatitis A 15
Table 7: Differential Diagnosis of hepatitis A 15
Table 8: Havrix Dosage and Schedule for Vaccination 16
Table 9: Vaqta Dosage and Schedule for Vaccination 16
Table 10: Twinrix Dosage and Schedule for Vaccination 16
Table 11: UK Guidelines For Hepatitis A Vaccination 17
Table 12: Japanese Hepatitis A Vaccine, Dosage and Schedule 17
Table 13: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2006-2011 21
Table 14: Hepatitis A Preventive Vaccines Market, Global, Forecast ($m), 2011-2019 22
Table 15 Hepatitis A Preventive Vaccines Market, The US, Revenue ($m), 2006-2011 23
Table 16: Hepatitis A Preventive Vaccines, The US, Forecast ($m), 2011-2019 24
Table 17: Hepatitis A Preventive Vaccines Market, France, Revenue ($m), 2006-2011 25
Table 18: Hepatitis A Preventive Vaccines, France, Forecast ($m), 2011-2019 26
Table 19: Hepatitis A Preventive Vaccines Market, Germany, Revenue ($m), 2006-2011 27
Table 20: Hepatitis A Preventive Vaccines Market, Germany, Forecast ($m), 2011-2019 28
Table 21: Hepatitis A Preventive Vaccines Market, Italy, Revenue ($m), 2006-2011 29
Table 22: Hepatitis A Preventive Vaccines Market, Italy, Forecast ($m), 2011-2019 30
Table 23: Hepatitis A Preventive Vaccines Market, Spain, Revenue ($m), 2006-2011 31
Table 24: Hepatitis A Preventive Vaccines, Spain, Forecast ($m), 2011-2019 32
Table 25: Hepatitis A Preventive Vaccines Market, The UK, Revenue ($m), 2006-2011 33
Table 26: Hepatitis A Preventive Vaccines Market, The UK, Forecast ($m), 2011-2019 34
Table 27: Hepatitis A Market, Japan, Revenue ($m), 2006-2011 35
Table 28: Hepatitis A Preventive Vaccines Market, Japan, Forecast ($m), 2011-2019 36
Table 29: Hepatitis A Preventive Vaccines - Clinical Trials by Region/ Country, 2012 48
Table 30: Hepatitis A Preventive Vaccines - Clinical Trials by Phase, 2012 49
Table 31: Hepatitis A Preventive Vaccines - Clinical Trials by Status, 2012 50
Table 32: Hepatitis A Preventive Vaccines - Prominent Sponsors, 2012 51
Table 33: Hepatitis A Preventive Vaccines - Overall Sponsors, 2012 52
Table 34: Hepatitis A Preventive Vaccines - Top Companies Participating in Clinical Trials, 2012 53

List of Figures


Figure 1: Prevalence of Hepatitis A Virus by Region 8
Figure 2: Incidence of Hepatitis A, 1980-2009 10
Figure 3: Pathophysiology of Hepatitis A 12
Figure 4 : Symptoms of Hepatitis A infection 13
Figure 5: Referral Pathway for HAV Vaccination 18
Figure 6: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan 19
Figure 7: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2006-2011 21
Figure 8: Hepatitis A Preventive Vaccines Market, Global, Forecast ($m), 2011-2019 22
Figure 9 Hepatitis A Preventive Vaccines, The US, Revenue ($m), 2006-2011 23
Figure 10: Hepatitis A Preventive Vaccines, The US, Forecast ($m), 2011-2019 24
Figure 11: Hepatitis A Preventive Vaccines Market, France, Revenue ($m), 2006-2011 25
Figure 12: Hepatitis A Preventive Vaccines, France, Forecast ($m), 2011-2019 26
Figure 13: Hepatitis A Preventive Vaccines Market, Germany, Revenue ($m), 2006-2011 27
Figure 14: Hepatitis A Preventive Vaccines Market, Germany, Forecast ($m), 2011-2019 28
Figure 15: Hepatitis A Preventive Vaccines Market, Italy, Revenue ($m), 2006-2011 29
Figure 16: Hepatitis A Preventive Vaccines Market, Italy, Forecast ($m), 2011-2019 30
Figure 17: Hepatitis A Preventive Vaccines Market, Spain, Revenue ($m), 2006-2011 31
Figure 18: Hepatitis A Preventive Vaccines Market, Spain, Forecast ($m), 2011-2019 32
Figure 19: Hepatitis A Preventive Vaccines Market, The UK, Revenue ($m), 2006-2011 33
Figure 20 : Hepatitis A Preventive Vaccines Market, The UK, Forecast ($m), 2011-2019 34
Figure 21 : Hepatitis A Preventive Vaccines Market, Japan, Revenue ($m), 2006-2011 35
Figure 22: Hepatitis A Preventive Vaccines Market, Japan, Forecast ($m), 2011-2019 36
Figure 23: Opportunity and Unmet Need in the Hepatitis A Preventive Vaccines Market, 2012 38
Figure 24: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan 39
Figure 25: Hepatitis A Preventive Vaccines - Strategic Competitor Assessment, 2012 41
Figure 26: KOL Insights, Hepatitis A Preventive Vaccines in the US, Europe and Japan 47
Figure 27: Hepatitis A Preventive Vaccines - Clinical Trials by Country, 2012 48
Figure 28: Hepatitis A Preventive Vaccines - Clinical Trials by Phase, 2012 49
Figure 29: Hepatitis A Preventive Vaccines - Clinical Trials by Status, 2012 50
Figure 30: Hepatitis A Preventive Vaccines - Prominent Sponsors, 2012 51
Figure 31: Hepatitis A Preventive Vaccines - Overall Sponsors, 2012 52
Figure 32: Hepatitis A Preventive Vaccines - Top Companies Participating in Clinical Trials, 2012 53
Figure 33: Hepatitis A Preventive Vaccines Market - Drivers and Restraints 2012 54
Figure 34: Implications for Future Market Competition in Hepatitis A Preventive Vaccines Market, 2012 55
Figure 35: Hepatitis A Preventive Vaccines - Marketed Products by Company, 2012 56
Figure 36: KOL Insights, Hepatitis A Preventive Vaccines, Major Market 58
Figure 37: GlobalData Market Size Estimation 62
Figure 38 : GlobalData Market Forecasting Model 64

Upcoming Reports:

Chronic Myeloid Leukemia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Chronic Myeloid Leukemia (CML) is a type of blood cancer caused by uncontrolled growth of the cells in bone marrow. CML is a type of myeloproliferative disease which is characterized by the chromosomal translocation. Patients suffering from CML show increased susceptibility to infections, thrombocytopenia, anemia and may also have enlarged spleen which causes pain on the left side. Incidence rate of CML is high in men and is the second most common type of cancer occurring in male adults. Women who are above 50 years in age are expected to suffer from this chronic disease. Treatment...
Physician Office Laboratory (POL) Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Physician office lab (POL) term is wide and diverse, it encompasses physician’s practices as small (2 to 5 doctors) to large practitioners (200 physicians) that operate labs similar to small laboratory hospitals. Hospitals and commercial labs perform tests, but physicians prefer to perform in-house testing in order to enhance the patient care. In-house testing facilitates physicians to no longer rely on the reference labs for test results. In addition, physicians can obtain faster results from their own labs and increase profits. POL also reduces the chances of loss or...
Online Banking Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
By - Transparency Market Research
Online banking is a service provided by financial institutions that allows customers to carry out financial transactions through secure websites. Many customers are turning towards the convenience and ease of online banking to carry out their financial transactions. These websites can be operated through a virtual bank by using a retail operator or through a credit union. With online banking, customers can conduct transactions such as account management, money transfer, bill payments, maintenance, and many other tasks.  With growing customer base and the growing number of...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Increased Freedom for Siemens Healthcare Through Reworked Board
Jan 27, 2015  
Siemens Chief Executive Officer, Joe Kaeser, has successfully reshuffled the management board of the company. The largest engineering company in Europe, Siemens, is now ready to submit its healthcare operations to greater internal independence. Bernd Montag has been approached to take care of the healthcare unit. On the other hand, chief technology officer and personnel chief Siegfried...
Declining Oil Prices in Vietnam - Problematic for Managing the Budget Deficit
Jan 27, 2015  
Falling prices of oil are fuelling the domestic consumption pattern in Vietnam and is as a result giving a significant boost to the Vietnamese economy. This is also presenting a dilemma for the government since the country’s efforts to control the budget deficit is also getting threatened. As per Bui Duc Thu, a member of the National Assembly’s finance committee, a certain decline...
Oil Prices by far the Lowest in Six Years
Jan 27, 2015  
In almost six years, the amount of oil traded reached the lowest levels since the OPEC’s warning that prices may rise without new investment in production that failed to shift the focus of the market from more immediate signs of a global supply glut. As per the OPEC Secretary-General Abdalla El-Badri changes in futures were quite low in New York after declining 1% on Monday. A hike to...
The Georgia Deal to Fuel the Southern Solar Strategy
Jan 27, 2015  
It is anticipated that the southern part of U.S. will become the center of the solar industry within the next six to twelve months if all goes as per plans in Georgia. In January, a compromise bill was introduced by Mike Dudgeon, the State Representative on the third-party ownership of solar systems in the state. As per this legislation, companies like Sungevity or SolarCIty can install...
Fund for Innovative Technologies Set Up by Hyundai Motor
Jan 27, 2015  
Hyundai Motor Group on Tuesday announced that it will be launching a fund worth US$163.9 million in order to aid business ventures and the development of innovative technologies with regard to automobiles and hydrogen fuel cells. With ownership of two of South Korea’s largest car manufacturers – Kia Motors Corp. and Hyundai Motor Co., Hyundai Motor Group said that of the 177.5...